Book a Call
MDside
Book a Call

GHK-Cu copper peptide: the mechanism of action, step by step

  • MDside
  • October 9, 2026

GHK-Cu has one of the best-described mechanisms among cosmetic peptides, and almost all of it was measured in cells and rats. It delivers copper, stimulates collagen and other matrix components, and modulates the enzymes that remodel tissue. The human evidence is thin: of 9 published human studies, 4 are controlled with GHK-Cu as the main agent, and their results are mixed.

Key points

  • GHK binds copper with a dissociation constant on the order of 10⁻¹⁴ M and facilitates its uptake into cells [3][5].
  • In fibroblasts, GHK-Cu was associated with more collagen (peak at 10⁻⁹ M), glycosaminoglycans and decorin [10][12][13].
  • It also increased MMP-2 and, at the same time, its inhibitors TIMP-1 and TIMP-2 [14].
  • The gene-expression data (Connectivity Map) are computational and cell-line analyses. They are not clinical trials [21][22].
  • We verified 9 human studies. Only 4 are controlled with GHK-Cu as the main agent, with mixed results [24][25][26][27].

US status (October 2026): Not FDA-approved; topical GHK-Cu is returning to 503A Category 1, while injectable GHK-Cu has no pathway and carries an FDA immunogenicity warning. See the GHK-Cu status page.

GHK is a serum tripeptide that falls with age

GHK (glycyl-L-histidyl-L-lysine) is a tripeptide that Loren Pickart identified in human serum in 1973, as an activity that prolonged the survival of normal liver cells [1]. According to his group’s reviews, it is present in plasma, saliva and urine, and its plasma concentration falls from about 200 ng/mL at age 20 to about 80 ng/mL at age 60 [2]. Two findings suggest the body also generates it locally. The GHK sequence sits within the α2 chain of type I collagen, from which it could be released by proteolysis in a wound [10], and breakdown of the matrix protein SPARC releases GHK and KGHK [20]. This article covers mechanism. The critical analysis of the trials is in GHK-Cu: four decades of papers, few trials.

Step 1: copper is the starting point

The first proposed mechanism was copper transport. During its isolation, GHK co-eluted with nearly equimolar copper. The tripeptide forms complexes with copper(II) and increased uptake of the metal into cultured hepatoma cells [3]. Its binding site resembles the copper-transport site of albumin: at equimolar albumin and peptide, about 42% of the copper was bound to GHK [4]. By calorimetry, the conditional dissociation constant of the complex at pH 7.4 was 7.0 × 10⁻¹⁴ M, in a 1:1 ratio [5].

Skin needs copper because copper is a cofactor of the lysyl oxidase family, the enzymes that cross-link collagen and elastin [6]. We found no study measuring lysyl oxidase activity with GHK-Cu as the sole agent. In a combined system (GHK-Cu as the copper source plus mRNA for the chaperone ATOX1), that enzyme’s activity rose to 1.78 times control [7]. Superoxide dismutase (SOD) is similar. GHK-Cu increased SOD activity in macrophages and in mice with lung injury [8], but the complex itself showed no significant SOD-like activity [9]. The effect looks indirect, acting through the cell.

Step 2: more matrix, with balanced remodeling

The strongest mechanistic data concern the extracellular matrix, and almost all of them come from François-Xavier Maquart’s laboratory in Reims:

TargetFindingModel
CollagenSynthesis rose from 10⁻¹² to 10⁻¹¹ M, peaking at 10⁻⁹ M, with no change in cell number [10]Fibroblast culture
GlycosaminoglycansDose-dependent, biphasic increase, peaking between 10⁻⁹ and 10⁻⁸ M; mainly dermatan sulfate and heparan sulfate, no effect on hyaluronic acid [12]Fibroblast culture
Connective tissueMore dry weight, DNA, protein, collagen and glycosaminoglycans; collagen stimulation twice that of other proteins, with more type I and III collagen mRNA [11]Rat wound chambers
DecorinMore decorin mRNA, less biglycan mRNA [13]Rat wounds

Reviews from Pickart’s group add elastin to that list [16]. In dermal fibroblasts, GHK-Cu increased MMP-2 (an effect reproduced by copper alone, and absent with copper-free GHK) and, at the same time, secretion of its inhibitors TIMP-1 and TIMP-2 [14]. In ischemic rat wounds, by contrast, treated tissue had less MMP-2, MMP-9 and TNF-α than controls, and wound area shrank by 64.5% by day 13, versus 45.6% with vehicle [15]. The pattern is context-dependent modulation of proteases. It is neither a simple increase nor a blockade.

Step 3: cells, vessels and inflammation

  • Keratinocytes: in culture, the complex increased proliferation. In skin-equivalent models, it increased p63, PCNA and integrins α6 and β1 [17].
  • Irradiated fibroblasts: at 10⁻⁹ M, they divided faster and produced more bFGF and VEGF than controls early after exposure [18]. In keloid fibroblasts, copper tripeptide reduced TGF-β1 secretion at 24 hours [19].
  • Vessels: SPARC-derived KGHK peptides stimulated angiogenesis in vivo. That activity did not depend on bound copper [20].
  • Inflammation and oxidation: in macrophages and mice, lower reactive oxygen species, TNF-α and IL-6, through suppression of NF-κB p65 and p38 MAPK [8]. In vitro, GHK-Cu inhibited iron release from ferritin and the lipid peroxidation that depends on it [9].

Step 4: the gene signature is a hypothesis

From 2010 a broader mechanism was proposed: modulation of gene expression. An independent team used the Broad Institute’s Connectivity Map tool and found that GHK reversed the gene signature of emphysematous destruction (127 genes) and, in human fibroblasts, restored collagen I contraction and remodeling in cells from COPD patients [21]. Pickart’s group later analyzed GHK’s profiles in that database. They come from 2 tumor cell lines (PC3 and MCF7), and 31.2% of genes changed expression by 50% or more [22]. Their reviews cite at least 4,000 human genes [2]. These are computational and cell-culture analyses. They generate hypotheses and do not show an effect in a person’s skin.

In the hair follicle, the most cited ex vivo data used a sister molecule, AHK-Cu (alanyl-histidyl-lysine-copper). At 10⁻¹² to 10⁻⁹ M it elongated cultured human follicles and stimulated proliferation of dermal papilla cells [23].

Every human study we could verify

We searched PubMed and the reference lists of the 2026 reviews [6][37]. These are the human studies with published results.

  • Diabetic ulcers (1994): multicenter, randomized, evaluator-blinded, vehicle-controlled; GHK-Cu gel. Median area closure of 98.5% vs 60.8%, and, in plantar ulcers treated right after debridement, infections in 7% vs 34% [24].
  • Venous ulcers (1992): randomized, evaluator-blinded, 86 patients; 0.4% copper tripeptide cream vs 1% silver sulfadiazine and placebo. No difference from placebo; silver sulfadiazine was superior [25].
  • After CO2 laser (2006): randomized, 13 patients, 12 weeks; regimen with or without GHK-Cu. No objective differences in erythema or wrinkles; higher satisfaction with GHK-Cu (P = .04) [26].
  • Sparse eyebrows (2026, conference proceedings): randomized, double-blind, placebo-controlled, split-face; 18 participants, 2% GHK-Cu serum twice daily for 12 weeks. Significant increase in hair count and diameter on the treated side [27].
  • Androgenetic alopecia (2016): 45 men, 6 months, 5-aminolevulinic acid and GHK complex (no copper stated) vs placebo; hair-count increase of 52.6 and 71.5 vs 9.6 [28].
  • Androgenetic alopecia (2025): retrospective, 7 men, 5 monthly sessions of minoxidil, dutasteride and copper peptides by tattooing, no control group; median regrowth of 26.5% [29].
  • Hair loss (2018): open-label, single-arm, 1,000 patients; intradermal injections of a formulation with growth factors and copper tripeptide-1, 8 sessions every 3 weeks; less shedding in 83% on the pull test [30].
  • Multi-ingredient cosmetics (2024 and 2025): open-label, uncontrolled manufacturer studies with copper tripeptide-1 among other actives: dandruff over 15 days [31] and acne scars over 45 days [32].

Only the first 4 are controlled and test GHK-Cu as the main agent. A randomized, double-blind phase 2 trial of a GHK-Cu gel versus vehicle in standardized acute wounds, with 60 estimated participants, is still recruiting [33]. For its use in regenerative blends, see GLOW, KLOW and Wolverine blends.

In dermatomed human skin, under infinite-dose conditions over 48 hours, 136.2 µg/cm² of copper applied as the tripeptide permeated and 82 µg/cm² was retained in the tissue. The method measured copper, not intact peptide [34]. Through intact human skin, almost no peptide or copper passed in 9 hours. After microneedle pretreatment, 134 nmol of peptide and 705 nmol of copper permeated, with no signs of irritation [35]. A 2025 review concluded that metal complexation and hydrophobic modification increase GHK’s permeability, and that microneedles deserve further study [36].

The limits are as specific as the mechanism

  • Almost all of the mechanism is in vitro or animal. Collagen, decorin, MMP/TIMP and angiogenesis data come from cultures and rats [10][11][13][14][15].
  • Few independent trials. A 2025 review noted “a surprising absence of clinical studies” with GHK-Cu and Pal-GHK [36].
  • Concentrated authorship. About 35% of the primary literature includes Pickart or Anna Margolina (Skin Biology) as authors [6]. Pickart isolated the peptide and, according to that review, held commercial interests for decades [6].
  • The molecule is not always the same. AHK-Cu, copper-free GHK and multi-ingredient formulas are not equivalent to GHK-Cu [23][28][30], and the 2026 review warns that coordination state, speciation and stability vary with formulation [37].

What this means for you

GHK-Cu supplies copper, stimulates collagen, glycosaminoglycans and decorin, and modulates MMPs and their inhibitors at the same time [5][10][13][14]. The most recent review calls it “promising but unproven” as a therapeutic agent until controlled clinical trials are available [37]. The open clinical question is how much reaches the dermis intact and with what result. Keep GHK-Cu to topical use, keep your marketing to appearance language, and source it as a cosmetic or as a 503A preparation for a named patient; the 503A vs 503B sourcing guide explains the difference. Our peptide programs run on that line.

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PMID 4349963. Link
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID 26236730. Link
  3. Pickart L, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-7. PMID 7453802. Link
  4. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PMID 7340824. Link
  5. Trapaidze A, et al. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID 21898044. Link
  6. Najafi N, et al. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. PMID 42787770. Link
  7. Wang R, et al. Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins’ activity for fascia regeneration. J Control Release. 2026;390:114521. PMID 41371501. Link
  8. Park JR, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID 27517151. Link
  9. Miller DM, DeSilva D, Pickart L, Aust SD. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79-84. PMID 2244543. Link
  10. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PMID 3169264. Link
  11. Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. PMID 8227353. Link
  12. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-56. PMID 1522753. Link
  13. Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-8. PMID 11121126. Link
  14. Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. PMID 11045606. Link
  15. Canapp SO Jr, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-23. PMID 14648529. Link
  16. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520. Link
  17. Kang YA, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-6. PMID 19319546. Link
  18. Pollard JD, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID 15655171. Link
  19. McCormack MC, Nowak KC, Koch RJ. The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model. Arch Facial Plast Surg. 2001;3(1):28-32. PMID 11176716. Link
  20. Lane TF, et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol. 1994;125(4):929-43. PMID 7514608. Link
  21. Campbell JD, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID 22937864. Link
  22. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PMID 25302294. Link
  23. Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-9. PMID 17703734. Link
  24. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PMID 17147644. Link
  25. Bishop JB, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. PMID 1495150. Link
  26. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PMID 16847171. Link
  27. Bo SL, et al. The efficacy of 2% copper peptide (GHK-Cu) serum for eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled, split-face comparative study. Procedia of Multidisciplinary Research. 2026;4(5). Link
  28. Lee WJ, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016;28(4):438-43. PMID 27489425. Link
  29. Kuceki G, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD Int. 2025;20:38-40. PMID 40225275. Link
  30. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth – safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20(6):369-379. PMID 29482481. Link
  31. Patel MN, et al. An assessment of the safety, efficacy, and tolerability of a novel scalp treatment regimen combining a hydroxy acid-based scrub and copper tripeptide serum in the management of seborrheic dermatitis in adults. Cureus. 2024;16(9):e70108. PMID 39449909. Link
  32. Patel MN, et al. Efficacy and safety assessment of ThriveCo Scar Fader Gel with Scarcede in the treatment of skin scars. Cureus. 2025;17(8):e90934. PMID 41001334. Link
  33. ClinicalTrials.gov. NCT07437586: A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults. Accessed October 9, 2026. Link
  34. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010;59(11):983-8. PMID 20703511. Link
  35. Li H, et al. Microneedle-mediated delivery of copper peptide through skin. Pharm Res. 2015;32(8):2678-89. PMID 25690343. Link
  36. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts. 2025;15:30071. PMID 39963574. Link
  37. Mateescu DM, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics. 2026;18(9):1077. PMID 42797253. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.